Related Experiment Video
Updated: Aug 29, 2026

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR)
Cor A Berrevoets1, Arzu Umar, Jan Trapman
1Department of Reproduction and Development, Erasmus MC, University Medical Center Rotterdam, 3000 DR Rotterdam, Netherlands. c.berrevoets@erasmusmc.nl
Abstract:
Antiandrogens are widely used agents in the treatment of prostate cancer, as inhibitors of AR (androgen receptor) action. Although the precise mechanism of antiandrogen action is not yet elucidated, recent studies indicate the involvement of nuclear receptor co-repressors. In the present study, the regulation of AR transcriptional activity by N-CoR (nuclear receptor co-repressor), in the presence of different ligands, has been investigated. Increasing levels of N-CoR differentially affected the transcriptional activity of AR occupied with either agonistic or antagonistic ligands. Small amounts of co-transfected N-CoR repressed CPA (cyproterone acetate)- and mifepristone (RU486)-mediated AR activity, but did not affect agonist (R1881)-induced AR activity. Larger amounts of co-transfected N-CoR repressed AR activity for all ligands, and converted the partial agonists CPA and RU486 into strong AR antagonists. In the presence of the agonist R1881, co-expression of the p160 co-activator TIF2 (transcriptional intermediary factor 2) relieved N-CoR repression up to control levels. However, in the presence of RU486 and CPA, TIF2 did not functionally compete with N-CoR, suggesting that antagonist-bound AR has a preference for N-CoR. The AR mutation T877A (Thr877-->Ala), which is frequently found in prostate cancer and affects the ligand-induced conformational change of the AR, considerably reduced the repressive action of N-CoR. The agonistic activities of CPA- and hydroxyflutamide-occupied T877A-AR were hardly affected by N-CoR, whereas TIF2 strongly enhanced their activities. These results indicate that lack of N-CoR action allows these antiandrogens to act as strong agonists on the mutant AR.
Insights
Nuclear receptor co-repressor N-CoR regulates androgen receptor (AR) activity differently with various ligands. N-CoR represses antiandrogen activity, especially on mutant AR, impacting prostate cancer treatment.
Area of Science:
- Molecular Biology
- Endocrinology
- Cancer Research
Background:
- Antiandrogens are crucial for prostate cancer treatment by inhibiting androgen receptor (AR) action.
- The precise mechanisms of antiandrogen action are not fully understood, but nuclear receptor co-repressors are implicated.
- Nuclear receptor co-repressor (N-CoR) plays a role in regulating AR transcriptional activity.
Purpose of the Study:
- To investigate the regulation of AR transcriptional activity by N-CoR in the presence of different ligands.
- To understand how N-CoR affects AR activity with agonists versus antagonists.
- To examine the influence of N-CoR on AR activity in the context of prostate cancer-associated mutations.
Main Methods:
- Investigated AR transcriptional activity using co-transfection assays with varying N-CoR levels.
- Tested the effects of different ligands, including agonists (R1881) and partial agonists/antagonists (cyproterone acetate [CPA], mifepristone [RU486]).
- Examined the interplay between N-CoR, co-activator TIF2, and wild-type versus T877A mutant AR.
Main Results:
- N-CoR repressed CPA- and RU486-mediated AR activity at low levels, but not R1881-induced activity.
- Higher N-CoR levels repressed AR activity for all ligands and converted partial agonists into antagonists.
- TIF2 relieved N-CoR repression for agonists but not for antagonists, indicating antagonist-bound AR preference for N-CoR.
- The T877A AR mutation significantly reduced N-CoR repression, allowing antiandrogens to act as agonists.
Conclusions:
- N-CoR differentially regulates AR transcriptional activity based on ligand type and concentration.
- Antagonist-bound AR shows a preference for N-CoR over co-activator TIF2.
- The T877A mutation in AR diminishes N-CoR's repressive function, potentially leading to antiandrogen agonism in prostate cancer.
Related Concept Videos
Co-activators and Co-repressors
Co-activators and Co-repressors
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
RNA Polymerase II Accessory Proteins
Internal Receptors
Master Transcription Regulators

